keyword
MENU ▼
Read by QxMD icon Read
search

Heart failure treatment

keyword
https://www.readbyqxmd.com/read/28945046/-analysis-of-on-medication-rules-for-qi-deficiency-and-blood-stasis-syndrome-of-chronic-heart-failure-based-on-data-mining-technology
#1
Qian Wang, Geng-Zhen Yao, Guang-Ming Pan, Jing-Yi Huang, Yi-Pei An, Xu Zou
To analyze the medication features and the regularity of prescriptions of traditional Chinese medicine in treating patients with Qi-deficiency and blood-stasis syndrome of chronic heart failure based on modern literature. In this article, CNKI Chinese academic journal database, Wanfang Chinese academic journal database and VIP Chinese periodical database were all searched from January 2000 to December 2015 for the relevant literature on traditional Chinese medicine treatment for Qi-deficiency and blood-stasis syndrome of chronic heart failure...
January 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/28944989/the-combination-of-valsartan-and-sacubitril-in-the-treatment-of-hypertension-and-heart-failure-an-update
#2
Peter Munch Nielsen, Daniela Grimm, Markus Wehland, Ulf Simonsen, Marcus Krüger
A novel antihypertensive drug, LCZ696 (Entresto(®) ), has recently been introduced, which combines the action of an antagonist of the renin-angiotensin-aldosterone-system (RAAS), effectively decreasing the blood pressure, with an inhibition of neprilysin, which is responsible for metabolizing natriuretic peptides exerting anti-hypertensive and anti-fibrotic effects. In this MiniReview, we describe the pharmacokinetics and -dynamics, efficacy and side effects of the combined angiotensin receptor antagonist and neprilysin inhibitor LCZ696...
September 25, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28944588/left-ventricular-perforation-after-impella%C3%A2-placement-in-a-patient-with-cardiogenic-shock
#3
David C Peritz, Lee Linstroth, Craig H Selzman, Edward M Gilbert
Mechanical cardiovascular support devices are now widely used both in the setting of cardiogenic shock as well as during high risk cardiac catheterization procedures. We report a case of a young female patient who presented with presumed myocarditis and rapidly deteriorating decompensated heart failure requiring the implantation of an Impella Circulatory Support System. Upon transfer to our facility it was discovered that during transport, the Impella device had migrated through the left ventricle. She was emergently taken to the operating room where the Impella was surgically removed and biventricular support devices were placed...
September 25, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28944227/neonatal-enterovirus-myocarditis-with-severe-dystrophic-calcification-novel-treatment-with-pocapavir
#4
Samuel G Wittekind, Catherine C Allen, John L Jefferies, Mantosh S Rattan, Peace C Madueme, BreAnn N Taylor, Ryan A Moore
Dystrophic myocardial calcification occurs in the setting of myocardial injury and normal serum calcium. We present a case of a neonate with prominent dystrophic calcification and severe left ventricular systolic dysfunction in the setting of enterovirus myocarditis. These findings are superbly illustrated by multiple imaging modalities. The patient was treated with the novel antiviral, pocapavir, in addition to a standard heart failure regimen. The dystrophic calcification persisted but the left ventricle remodeled significantly...
July 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28944178/alcohol-septal-ablation-in-which-patients-and-why
#5
Paolo Spirito, Jessica Rossi, Barry J Maron
At present, surgical septal myectomy is regarded as the "gold standard" treatment for most patients with obstructive hypertrophic cardiomyopathy (HCM) and drug-refractory symptoms. However, the best results are obtained by those surgeons who have extensive experience with this operation at a small number of referral centers. In the mid-1990s, percutaneous alcohol septal ablation was introduced as an alternative to myectomy to reduce LV outflow gradient and heart failure symptoms in patients with obstructive HCM...
July 2017: Annals of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/28944176/results-of-surgical-septal-myectomy-for-obstructive-hypertrophic-cardiomyopathy-the-tufts-experience
#6
Hassan Rastegar, Griffin Boll, Ethan J Rowin, Noreen Dolan, Catherine Carroll, James E Udelson, Wendy Wang, Philip Carpino, Barry J Maron, Martin S Maron, Frederick Y Chen
BACKGROUND: For over 50 years, surgical septal myectomy has been the preferred treatment for drug-refractory heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Over this time in the United States, the majority of myectomy operations have been performed in a small number of select referral centers. METHODS: We have taken the opportunity to report results from the relatively new Tufts HCM Center and surgical program, incorporated 13 years ago, during which 507 myectomies (52±14 years of age; 56% male) were performed by one cardiothoracic surgeon, Dr...
July 2017: Annals of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/28944175/long-term-outcome-of-simultaneous-septal-myectomy-and-anterior-mitral-leaflet-retention-plasty-in-hypertrophic-obstructive-cardiomyopathy-the-berlin-experience
#7
Eva Maria Delmo Walter, Mariano Francisco Javier, Roland Hetzer
BACKGROUND: Various surgical strategies designed to relieve left ventricular outflow tract obstruction (LVOTO) and correct mitral regurgitation (MR) in hypertrophic obstructive cardiomyopathy (HOCM) have evolved, yet reports on the long-term outcomes of each technique are scarce. We provide an update on over 20 years' experience at our institution in the standardized surgical treatment of HOCM. METHODS: Between April 1986 and April 2014, 320 cases of endomyocardial resection and 305 septal myectomies were performed at our institution...
July 2017: Annals of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/28943262/effectiveness-of-a-patient-education-programme-in-heart-failure-with-preserved-ejection-fraction-results-from-the-odin-cohort-study-using-propensity-score-matching
#8
Nelly Agrinier, Matthieu Schockmel, Nathalie Thilly, Hervé Laborde-Castérot, Patrick Jourdain, François Alla, Christophe Leclercq, François Dany, Justine Druelle, Emilie Drouet, Geneviève Mulak, Yves Juillière
BACKGROUND: Patient education programmes (PEP) are recommended for patients with heart failure but have not been specifically assessed in heart failure with preserved ejection fraction (HFpEF). AIM: To assess the effectiveness of a structured PEP in reducing all-cause mortality in patients with HFpEF. METHODS: Patients with HFpEF were selected from the ODIN cohort, designed to assess PEP effectiveness in patients with HF whatever their ejection fraction, included from 2007 to 2010, and followed up until 2013...
September 21, 2017: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/28943106/at2-receptor-agonist-compound-21-a-silver-lining-for-diabetic-nephropathy
#9
REVIEW
Anuradha Pandey, Anil Bhanudas Gaikwad
The currently available therapies for diabetic nephropathy, one of the leading causes of renal failure globally are based on inhibition of renin angiotensin system. However, recently, the focus has shifted towards activation of its protective arm rather than the inhibition of deteriorative axis, using specific agonists. Compound 21 (C21), a novel non-peptide Angiotensin II type 2 receptor (AT2) agonist, recently granted orphan drug status for the treatment of a rare disease, idiopathic pulmonary fibrosis has also shown a potent anti-inflammatory, anti-fibrotic, antioxidant and anti-apoptotic potential in various diseases including heart failure, myocardial infarction, chronic inflammatory diseases, and neurological diseases such as ischemic stroke...
September 21, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28942975/real-world-outcomes-of-surgery-for-native-mitral-valve-endocarditis
#10
Nana Toyoda, Shinobu Itagaki, Natalia N Egorova, Henry Tannous, Anelechi C Anyanwu, Ahmed El-Eshmawi, David H Adams, Joanna Chikwe
BACKGROUND: Consensus guidelines recommend repair over replacement for the surgical treatment of active native mitral valve infective endocarditis. However, contemporary practice and long-term outcome data are limited. METHODS: Multivariable Cox regression was used to compare outcomes of 1970 patients undergoing isolated primary mitral valve repair (n = 367, 19%) or replacement (n = 1603, 81%) for active infective endocarditis between 1998 and 2010 in New York and California states...
September 1, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28942764/ocular-manifestations-of-obstructive-sleep-apnea
#11
Matthew Santos, R Jeffrey Hofmann
STUDY OBJECTIVES: Obstructive sleep apnea (OSA) incurs a host of systemic side effects. The eyes are particularly susceptible to both mechanical and vascular sequelae of the disease. This paper outlines the ocular manifestations of sleep apnea. The authors hope to increase awareness of the ocular complications of this common disorder and increase communication and co-management between eye-care providers and sleep specialists alike. METHODS: Data were collected from PubMed and the Brown University Library Collection...
September 20, 2017: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/28942666/-old-and-new-oral-anticoagulants-in-the-management-of-atrial-fibrillation-hungarian-data
#12
János Tomcsányi, Balázs Salfer, Bence Nagy
INTRODUCTION: Despite a progress in the management of patients with atrial fibrillation this arrhythmia is one of the major causes of stroke, heart failure, sudden death and cardiovascular morbidity. Oral anticoagulation with vitamin K antagonist or non-vitamin K antagonist markedly reduces stroke and mortality in atrial fibrillation patients. AIM: To estimate the real-life vitamin K antagonist and non-vitamin K antagonist oral anticoagulant treatment in past years in Hungary...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28942550/esc-position-paper-on-cardiovascular-toxicity-of-cancer-treatments-challenges-and-expectations
#13
Emanuel Raschi, Igor Diemberger, Benilde Cosmi, Fabrizio De Ponti
The recent position paper of the European Society of Cardiology (ESC) on cardiovascular toxicity of cancer treatments has attracted considerable interest by healthcare professionals, since it is the first concrete help in the difficult task of monitoring and approaching cardiovascular side effects of anticancer treatments. The ESC expert opinion was not intended as a clinical practice guideline; however, it reports major cardiovascular complications grouped into nine categories, addressing current clinical strategies for prevention and mitigation...
September 23, 2017: Internal and Emergency Medicine
https://www.readbyqxmd.com/read/28942281/antihypertrophic-effects-of-small-molecules-that-maintain-mitochondrial-atp-levels-under-hypoxia
#14
Hiroaki Nagai, Tomoko Satomi, Akiko Abiru, Kazumasa Miyamoto, Koji Nagasawa, Minoru Maruyama, Satoshi Yamamoto, Kuniko Kikuchi, Hiromitsu Fuse, Masakuni Noda, Yoshiyuki Tsujihata
Since impaired mitochondrial ATP production in cardiomyocytes is thought to lead to heart failure, a drug that protects mitochondria and improves ATP production under disease conditions would be an attractive treatment option. In this study, we identified small-molecule drugs, including the anti-parasitic agent, ivermectin, that maintain mitochondrial ATP levels under hypoxia in cardiomyocytes. Mechanistically, transcriptomic analysis and gene silencing experiments revealed that ivermectin increased mitochondrial ATP production by inducing Cox6a2, a subunit of the mitochondrial respiratory chain...
September 19, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28942152/relaxin-alleviates-tgf%C3%AE-1-induced-cardiac-fibrosis-via-inhibition-of-stat3-dependent-autophagy
#15
Yue Yuan, Yun Zhang, Xuejie Han, Yanyan Li, Xinbo Zhao, Li Sheng, Yue Li
Cardiac fibrosis is a pathological feature common to a variety of heart diseases such as myocardial infarction, arrhythmias, cardiomyopathies and heart failure. Emerging data has indicted that autophagy is involved in fibrotic synthesis. Relaxin as a pleiotropic hormone can attenuate cardiac fibrosis and hypertrophy, however the exact molecular mechanism remains largely unknown. In this work, we evaluated whether the antifibrotic effect of relaxin relies on regulating autophagy in primary cardiac fibroblasts (CFs)...
September 20, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28941608/economic-evaluation-of-left-ventricular-assist-devices-for-patients-with-end-stage-heart-failure-who-are-ineligible-for-cardiac-transplantation
#16
Derek S Chew, Braden Manns, Robert J H Miller, Nakul Sharma, Derek V Exner
BACKGROUND: Continuous flow (CF) left ventricular assist devices (LVADs) improve survival in end-stage heart failure patients who are ineligible for cardiac transplantation. Their use in this population (referred to as destination therapy) is increasing in many countries, yet they are not routinely funded for this indication in Canada. We assessed the cost-effectiveness of destination therapy CF-LVADs from the perspective of the Canadian health care payer. METHODS: A Markov model was used to project the outcomes and costs of 2 treatment pathways, CF-LVAD implantation and medical management alone, in an end-stage heart failure patient cohort ineligible for transplantation...
October 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28941606/new-developments-in-hypertrophic-cardiomyopathy
#17
REVIEW
Robert M Cooper, Claire E Raphael, Max Liebregts, Nandan S Anavekar, Josef Veselka
Hypertrophic cardiomyopathy is the leading cause of sudden death in young individuals and an important cause of heart failure at any age. In this review we discuss advances in investigation and management of this heterogenous disease. Improved cardiac imaging has allowed us to detail many of the structural abnormalities whereas the use of new techniques, predominantly in cardiac magnetic resonance imaging, has given us a greater insight in to tissue architecture, mechanism of contractile abnormalities, and function...
October 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28941600/comparison-of-mortality-and-nonfatal-cardiovascular-events-in-adults-with-atrial-fibrillation-with-versus-without-levothyroxine-treatment
#18
Per Wändell, Axel C Carlsson, Martin J Holzmann, Johan Ärnlöv, Jan Sundquist, Kristina Sundquist
Levothyroxine has been suggested to be cardiotoxic, but previous studies on the risk of cardiovascular events associated with levothyroxine treatment have been inconclusive. We aimed to study the association between levothyroxine treatment and all-cause mortality as well as cardiovascular events. Study population included all adults (n = 12,283) ≥ 45 years diagnosed with atrial fibrillation (AF) at 75 primary care centers in Sweden in 2001 to 2007, with (n = 1,189; 283 men and 906 women) or without (n = 11,094) levothyroxine treatment...
August 30, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28940112/iron-in-kidney-and-heart-failure-from-theory-to-practice
#19
REVIEW
Aslihan Yerlikaya, Mustafa C Bulbul, Baris Afsar, Tuncay Dagel, Gamze Aslan, Luminita Voroneanu, Dimitire Siriopol, Adrian Covic, Mehmet Kanbay
There is evidence that serum iron levels, regardless of the presence of anemia, directly impact outcomes in congestive heart failure (CHF) including quality of life, hospitalization rate and overall survival. Despite modern medical treatments, the prognosis of CHF remains grim. Ironically, simple iron replenishment may serve as a powerful tool in the armamentarium. This review will start from fundamental concepts of iron in oxygen delivery and analyze evidence-based outcomes in CHF iron-directed therapeutic trials...
September 22, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28940010/frequency-dependent-effects-of-omecamtiv-mecarbil-on-cell-shortening-of-isolated-canine-ventricular-cardiomyocytes
#20
Balázs Horváth, Norbert Szentandrássy, Roland Veress, János Almássy, János Magyar, Tamás Bányász, Attila Tóth, Zoltán Papp, Péter P Nánási
Omecamtiv mecarbil (OM) is a myosin activator agent developed for the treatment of heart failure. OM was reported to increase left ventricular ejection fraction and systolic ejection time, but little is known about the effect of heart rate on the action of OM. The present study, therefore, was designed to investigate the effects of OM on unloaded cell shortening and intracellular Ca(2+) ([Ca(2+)]i) transients as a function of the pacing frequency. Isolated cardiomyocytes were stimulated at various frequencies under steady-state conditions...
September 22, 2017: Naunyn-Schmiedeberg's Archives of Pharmacology
keyword
keyword
8454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"